There are still a large number of patients who do not respond well to this treatment, and the reason may be low expression of programmed death-ligand 1 (PD-L1), a “cold” tumor microenvironment (TME) characterized by a paucity of effector T cells or a surplus of immune regulatory cells [9–12]. Here, CD274 is linked to neoplasm.